Fluoroquinolone prescribing in the United States: 1995 to 2002
PURPOSE: To measure changes in the rate and type of fluoroquinolones prescribed in the
United States from 1995 to 2002. METHODS: We performed a longitudinal analysis of the …
United States from 1995 to 2002. METHODS: We performed a longitudinal analysis of the …
Pneumococcal conjugate vaccines for preventing vaccine‐type invasive pneumococcal disease and pneumonia with consolidation on x‐ray in children under two …
MG Lucero, VE Dulalia, RAN Parreño… - Cochrane Database …, 1996 - cochranelibrary.com
Background Pneumonia, most commonly caused by Streptococcus pneumoniae (Pnc), is a
major cause of morbidity and mortality among young children especially in developing …
major cause of morbidity and mortality among young children especially in developing …
Cefaclor revisited
BR Meyers - Clinical therapeutics, 2000 - Elsevier
OBJECTIVE: This paper describes the rationale for choosing cefaclor for the management of
respiratory tract infections. BACKGROUND: Since 1979, cefaclor has established a record of …
respiratory tract infections. BACKGROUND: Since 1979, cefaclor has established a record of …
Determination of cefaclor in human plasma by a sensitive and specific liquid chromatographic–tandem mass spectrometric method
X Chen, D Zhong, B Huang, J Cui - Journal of Chromatography B, 2003 - Elsevier
A sensitive and specific liquid chromatographic–tandem mass spectrometric method is
described for the determination of cefaclor in human plasma. The plasma samples were …
described for the determination of cefaclor in human plasma. The plasma samples were …
Clinical comparison of immediate-release cefaclor with a new extended-release formulation of cefaclor in outpatient infections
P Cole - Current therapeutic research, 1997 - Elsevier
A new extended-release formulation of cefaclor, a second-generation oral cephalosporin,
was developed to permit twice-daily (BID) dosing. When compared with immediate-release …
was developed to permit twice-daily (BID) dosing. When compared with immediate-release …
[图书][B] Pharmacokinetics and pharmacodynamics of cefaclor
A De la Peña - 2000 - search.proquest.com
The aim of this study was to use microdialysis and bacterial kill curves to develop a
pharmacokinetic-pharmacodynamic (PK-PD) model to describe the anti-infective effect of …
pharmacokinetic-pharmacodynamic (PK-PD) model to describe the anti-infective effect of …
[PDF][PDF] Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with...
M Lucero, VE Dulalia, H Nohynek - 2008 - academia.edu
Background Pneumonia, most commonly caused by Streptococcus pneumoniae (Pnc), is a
major cause of morbidity and mortality among young children especially in developing …
major cause of morbidity and mortality among young children especially in developing …
Cefaclor の安全性調査全国規模におけるprospective study
島田馨， 鈴木修二， 砂川慶介， 安田正俊… - 日本化学療法学会 …, 1995 - jstage.jst.go.jp
抄録 Cefaclor (CCL) 使用例におけるアナフィラキシー・ショック, 発疹などの過敏症状およびその他
重篤な副作用の発現頻度を正確に把握する目的で, 全国規模において prospective study …
重篤な副作用の発現頻度を正確に把握する目的で, 全国規模において prospective study …